TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19805674
Drug: Alemtuzumab 30
Normalized name: alemtuzumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab 30 mg IV three times weekly for up to 3 months and pentostatin 4 mg/m2 IV weekly for 4 weeks followed by alternate weekly administration for up to 6 months
Study: 19805674
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics including antiviral, antifungal, and antibacterial agents
Study: 16939066
Drug: Enteric-coated mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium (EC-MPS, myfortic) 720 mg b.i.d. with cyclosporine microemulsion and corticosteroids
Study: 11374602
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (2 x 10(6) KIU at induction, continuous infusion of 1 x 10(6) KIU/h, 1 x 10(6) KIU before reperfusion; n = 24)
Study: 11374602
Drug: Regular-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular-dose aprotinin (2 x 10(6) KIU at induction, continuous infusion of 0.5 x 10(6) KIU/h; n = 21)
Study: 1414239
Drug: Oxiracetam (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam (800 mg tablet), twice daily for 12 weeks
Study: 30316960
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sham intervention of similar dose)
Study: 29386172
Drug: Remote Collaborative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote Collaborative Depression Care (RCDC), N=65, 3-month treatment with continuous remote supervision by psychiatrists through shared electronic health records (SEHR) and phone monitoring.
Study: 22464674
Drug: Oral bacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bacterial lysate (heat‐killed Escherichia coli and Enterococcus faecalis) from week 5 until the end of month 7
Study: 20383345
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg once daily for 14 days
Study: 20383345
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg orally twice daily for 21 days
Study: 15750458
Drug: Oseltamivir (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (2 mg/kg)
Study: 12427146
Drug: N-acetylcysteine (NAC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC), 1200 mg one hour before angiography and a second dose 3 hours after; IV hydration
Study: 1399301
Drug: wide spectrum
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: wide spectrum intravenous antibiotics and suction and debridement
Study: 3160322
Drug: Cefazolin sodium
Normalized name: Cefazolin Sodium
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin sodium (20 mg/kg)
Study: 3160322
Drug: Cefoxitin sodium
Normalized name: Cefoxitin Sodium
DrugBank: Cefoxitin (DB01331)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefoxitin sodium (30 mg/kg)
Study: 18020888
Drug: No hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormonal replacement therapy
Study: 15516696
Drug: Telmisartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (80 mg daily)
Study: 9516894
Drug: Montelukast 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 100 mg once daily
Study: 8458257
Drug: Trimebutine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine (200 mg/day per os) for one month
Study: 25052238
Drug: Baclofen 10
Normalized name: baclofen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 10 mg 3 times daily for 5 days
Study: 25052238
Drug: Placebo 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg 3 times daily for 5 days
Study: 20395869
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg every day for 4 days
Study: 20395869
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice a day for 4 days
Study: 20395869
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg every day + Raltegravir 400 mg twice a day for 4 days
Study: 18315579
Drug: Clarithromycin 1
Normalized name: clarithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 1 g o.d. for 3 months
Study: 18315579
Drug: Clarithromycin 1
Normalized name: clarithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 1 g o.d. for 1 month
Study: 15737906
Drug: Urethral dose
Normalized name: Product manufactured as urethral dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urethral dose <150% minimum peripheral dose (mPD)
Study: 15737906
Drug: Urethral dose
Normalized name: Product manufactured as urethral dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urethral dose 150% minimum peripheral dose (mPD)
Study: 7004470
Drug: Propranolol 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 0.15 mg per kg body weight i.v.
Study: 31155472
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVR) injections
Study: 31454045
Drug: Tandem transplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem transplant with thiotepa/cyclophosphamide followed by dose-reduced carboplatin/etoposide/melphalan (n = 176)
Study: 28303328
Drug: Palmitoyl-KVK-L-ascorbic acid
Normalized name: palmitoyl collagen acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoyl-KVK-L-ascorbic acid cream
Study: 28303328
Drug: Palmitoyl-KVK-L-ascorbic acid
Normalized name: palmitoyl collagen acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoyl-KVK-L-ascorbic acid (20 μg/mL)
Study: 21537051
Drug: Combination vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination vitamin E (800 U), soy (40 g), and selenium (200 μg)
Study: 17578197
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with alpha-adrenoblockers
Study: 17578197
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with antibacterial drugs
Study: 15152897
Drug: sustained-release melatonin
Normalized name: melatonin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release melatonin 2 mg
Study: 8005275
Drug: Progesterone (P)
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone (P) 50 mg/d
Study: 8005275
Drug: Progesterone (P)
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone (P) 50 mg/d + Estrogen (E2) valerate 2 mg/d
Study: 2510272
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg b.d.
Study: 790546
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day of ketoprofen
Study: 790546
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day of phenylbutazone
Study: 790546
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (ketoprofen and phenylbutazone)
Study: 31491602
Drug: Radial approach
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial approach and bivalirudin treatment
Study: 27878824
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART)-based approach
Study: 20637053
Drug: 1,3-β-d-glucan-containing nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,3-β-d-glucan-containing nutritional supplement
Study: 18974448
Drug: Unipedal standing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unipedal standing therapy (3 times a day for an unspecified duration)
Study: 18974448
Drug: Unipedal standing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unipedal standing therapy
Study: 16550299
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 70 mg weekly
Study: 12741307
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - enoxaparine (100 IU/kg twice daily) for an average duration of 13 days, followed by fluindione starting on the fifth day.
Study: 8869692
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (2.5 mg/kg/day)
Study: 1512185
Drug: Alcohol treatment
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol treatment (maximal BALs of 0.05 or 0.10)
Study: 1512185
Drug: Alcohol treatment
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol treatment (ascending BALs)
Study: 1512185
Drug: Alcohol treatment
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol treatment (maximal intoxication)
Study: 6861866
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lorcainide tablets taken at 0, 12 and 24 h
Study: 6861866
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lorcainide tablets taken at 0, 1, 12 and 24 h
Study: 6861866
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lorcainide tablets taken at 0, 2, 12 and 24 h
Study: 26140541
Drug: Lipid (dairy-cream)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid (dairy-cream)
Study: 17900408
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 mg/day)
Study: 17900408
Drug: Rilmazafone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmazafone (2 mg/day)
Study: 11525272
Drug: Raloxifene hydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene hydrochloride, 60 mg/d for 6 months
Study: 9801723
Drug: Dual Focus
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual Focus Schema Therapy (manual-guided individual cognitive-behavioral therapy) for 24 weeks
Study: 9801723
Drug: 12-Step Drug
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-Step Drug Counseling
Study: 7949701
Drug: Zygapophysial joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zygapophysial joint injections or blocks of the medial branches of the dorsal ramus with lignocaine
Study: 29564750
Drug: Topical dressing
Normalized name: Gelocast, topical dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dressing formulated with 0.1% P1G10
Study: 24326198
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional orthodontic treatment without photobiomodulation)
Study: 18163011
Drug: Levothyroxine (L‐T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L‐T4) (n = 20)
Study: 11986705
Drug: Type B
Normalized name: HLA type B IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type B inactivated vaccine against HFRS
Study: 7801390
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser treatment (40 mW in 60 sec per cm tender tibia edge)
Study: 3294038
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) controlled-release tablets, 300 mg b.i.d.
Study: 27289174
Drug: Haemopoietic stem-cell
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemopoietic stem-cell gene therapy (HSC-GT) with autologous HSCs transduced with a lentiviral vector encoding ARSA cDNA after busulfan conditioning
Study: 24715381
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment for 2-5 years
Study: 19934404
Drug: Selective COX‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective COX‐2 inhibitor (celecoxib; 200 mg/dose, 600 mg total)
Study: 18385262
Drug: Nasal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal instillation of midazolam (0.2 mg kg(‐1))
Study: 18385262
Drug: Nebulized administration
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized administration of midazolam (0.2 mg kg(‐1))
Study: 16780390
Drug: simvastatin 5
Normalized name: simvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 5 mg/day (n = 10)
Study: 16780390
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg/day (n = 9)
Study: 16780390
Drug: control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (usual treatment; n = 8)
Study: 24432670
Drug: PMC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMC therapy combined with LFJC (Langchuang Fuzheng Jiedu Capsule)
Study: 24432670
Drug: PMC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMC therapy combined with LFJC
Study: 21596725
Drug: CEBM (Centre
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEBM (Centre for Evidence‐Based Medicine, Oxford)
Study: 12457031
Drug: Granisetron (GRN)
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron (GRN) alone (3 mg/patient)
Study: 12457031
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CCT) with Granisetron (GRN), Methylprednisolone (MPD) (250 mg/patient), and Droperidol (DRP) (0.5 ml/patient)
Study: 8363290
Drug: Tropicamide alone
Normalized name: Tropicamide
DrugBank: Tropicamide (DB00809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tropicamide alone or in combination with phenylephrine
Study: 3092196
Drug: hGRF 100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGRF 100, 300, and 600 micrograms (subcutaneous administration)
Study: 3092196
Drug: hGRF doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGRF doses above 80 micrograms
Study: 3092196
Drug: hGRF doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGRF doses less than 80 micrograms
Study: 27809592
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tamsulosin and Solifenacin
Study: 25944940
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen therapy (non-rebreathing face mask)
Study: 20024753
Drug: Directly Administered
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly Administered Antiretroviral Therapy (DAART)
Study: 17151339
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg rhGAA
Study: 17151339
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg rhGAA
Study: 17151339
Drug: rhGAA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGAA (both doses)
Study: 15096906
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg or Amlodipine 10 mg (after up-titration)
Study: 15096906
Drug: Valsartan +
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan + Hydrochlorothiazide (12.5 mg)
Study: 15096906
Drug: Amlodipine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine + Hydrochlorothiazide (12.5 mg)
Study: 11429364
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg amantadine IV in 500 mL saline
Study: 11429364
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL saline IV (Control group)
Study: 9554288
Drug: OMV vaccine
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMV vaccine with aluminium hydroxide and serogroup C-polysaccharide (C-ps)
Study: 9554288
Drug: OMV vaccine
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMV vaccine without aluminium hydroxide
Study: 9554288
Drug: OMV vaccine
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMV vaccine adsorbed to aluminium hydroxide
Study: 8052950
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level energy infra-red laser irradiation (4 minutes, total dose = 1J)
Study: 31125171
Drug: Dermocosmetic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermocosmetic treatments
Study: 23812462
Drug: Daily vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vaginal dilator use from postoperative weeks 4 through 8
Study: 19583607
Drug: Standard coronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard coronary bypass surgery without any additional medication (Control)
Study: 15630352
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for high-risk patients
Study: 15630352
Drug: Palliative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative chemotherapy for metastatic disease
Study: 15630352
Drug: Multimodality treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality treatment options (operation, chemotherapy, radiotherapy, biology therapy)
Study: 10037207
Drug: Prednisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (50 mg BID for 3 days)
Study: 8746921
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of 8 mg sublingual buprenorphine
Study: 8746921
Drug: Alternate-day dosing
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day dosing of 8 mg sublingual buprenorphine
Study: 2286597
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg i.v. ofloxacin per day
Study: 2286597
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 4000 mg piperacillin per day
Study: 7018639
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of glucagon intravenously
Study: 30180880
Drug: Conversational agent
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversational agent with high self-awareness
Study: 30180880
Drug: Conversational agent
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversational agent with low self-awareness
Study: 22724387
Drug: Other anti-epileptic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other anti-epileptic drugs
Study: 16238275
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of Dexamethasone every 12 hours for two doses (Group C, n=10)
Study: 10096580
Drug: anti-IFN-alpha vaccine
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-IFN-alpha vaccine
Study: 31953844
Drug: Mindlessness meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindlessness meditation (ML)
Study: 30452125
Drug: TIVA (propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA (propofol and remifentanil infusion)
Study: 30452125
Drug: DES (desflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES (desflurane inhalation and remifentanil infusion)
Study: 23262204
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of temsirolimus (25 mg IV weekly) and bevacizumab (10 mg/kg every other week)
Study: 23262204
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of temsirolimus and bevacizumab
Study: 19692044
Drug: Emollient cream
Normalized name: EMOLLIENT CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient cream (placebo group 1)
Study: 19692044
Drug: Topical triamcinolone
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triamcinolone (nonblinded treatment for nonresponders)
Study: 14763724
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (monthly education material and quarterly telephone calls)
Study: 3019810
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day mebeverine
Study: 28107891
Drug: Telephone-administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered cognitive behavioral stress management (T-CBSM), N=56
Study: 28107891
Drug: Live cognitive
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live cognitive behavioral stress management (L-CBSM), N=44
Study: 23184666
Drug: Anagrelide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide (1 mg) with food/caffeine (standardized breakfast including two cups of coffee)
Study: 23184666
Drug: Anagrelide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide (1 mg) in a fasted state
Study: 14528202
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (combination heat probe coagulation and injection therapy)
Study: 8826542
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg d-amphetamine (AMP)